A gene-editing tool called Crispr-Cas9 has sparked millions of dollars of investments. Two rival research teams that claim patents are going to court in the first stage of a battle set to determine who owns the commercial rights.
http://on.wsj.com/2guboBr
No comments:
Post a Comment